Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 known ✓ | P28845 | 4/20 | 0.52 |
| ▸ | HDAC4 known ✓ | P56524 | 3/20 | 0.48 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.42 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.55 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL501923 | 0.98 | AKR1C1 (0.57) | AKR1C1HSD11B1OPRL1HDAC4MEN1 | |
| SCHEMBL2722547 | 0.98 | AKR1C1 (0.57) | AKR1C1HSD11B1OPRL1HDAC4MEN1 | |
| SCHEMBL42114 | 0.89 | AKR1C1 (0.70) | AKR1C1HSD11B1OPRL1HDAC4MEN1 | |
| SCHEMBL2184245 | 0.89 | AKR1C1 (0.64) | AKR1C1HSD11B1OPRL1HDAC4MEN1 | |
| SCHEMBL43810 | 0.88 | AKR1C1 (0.68) | AKR1C1HSD11B1OPRL1HDAC4MEN1 | |
| Hydrochloric Acid SCHEMBL1990667 | 0.87 | OPRM1 (0.56) | AKR1C1HSD11B1OPRL1HDAC4HDAC1 | |
| SCHEMBL30662077 | 0.86 | AKR1C1 (0.46) | AKR1C1HSD11B1OPRL1HDAC1 | |
| SCHEMBL8366154 | 0.84 | OPRL1 (0.56) | AKR1C1HSD11B1OPRL1HDAC4MEN1 | |
| SCHEMBL476403 | 0.84 | OPRM1 (0.58) | AKR1C1HSD11B1OPRL1HDAC4HDAC1 | |
| SCHEMBL2703559 | 0.84 | ALDH1A1 (0.58) | AKR1C1OPRL1HDAC1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023033680-A1 | SUBSTITUTED 2,3,4,5-TETRAHYDROBENZO[ F][1,4]OXAZEPINES AS MODULATORS OF TRACE AMINE-ASSOCIATED RECEPTOR 1 (TAAR1) | LIMITED LIABILITY COMPANY «EXCELLENA RESEARCH AND DEVELOPMENT» (LLC «EXCELLENA») (RU) | 2023-03-09 | — | — | WO | claimed |
| WO-2023033680-A1 | SUBSTITUTED 2,3,4,5-TETRAHYDROBENZO[ F][1,4]OXAZEPINES AS MODULATORS OF TRACE AMINE-ASSOCIATED RECEPTOR 1 (TAAR1) | LIMITED LIABILITY COMPANY «EXCELLENA RESEARCH AND DEVELOPMENT» (LLC «EXCELLENA») (RU) | 2023-03-09 | — | — | WO | disclosed |
| WO-2015044962-A1 | AMORPHOUS FORM OF LEVOMILNACIPRAN HYDROCHLORIDE AND HYDRATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2015-04-02 | — | — | WO | disclosed |
| EP-2496079-A1 | NOVEL CRYSTALLINE FORMS OF (1S,2R)-2-(AMINO METHYL)-N,N-DIETHYL-1-PHENYL CYCLOPROPANE CARBOXAMIDE | Pierre Fabre Médicament SAS (FR) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011057176-A1 | NOVEL CRYSTALLINE FORMS OF (1S,2R)-2-(AMINO METHYL)-N,N-DIETHYL-1-PHENYL CYCLOPROPANE CARBOXAMIDE | Forest Laboratories Holding Limited (BM) | 2011-05-12 | — | — | WO | disclosed |
| EP-1558231-A2 | DOSAGE ESCALATION AND DIVIDED DAILY DOSE OF ANTI-DEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS | Cypress Bioscience, Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004030633-A2 | DOSAGE ESCALATION AND DIVIDED DAILY DOSE OF ANTI-DEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS | CYPRESS BIOSCIENCE, INC. (US) | 2004-04-15 | — | — | WO | disclosed |